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Novel therapeutic strategies are warranted in recurrent
ovarian cancer. We report two independent consecutive
studies of combinatorial immunotherapy comprising den-
dritic cell (DC)-based autologous whole tumor antigen
vaccination in combination with antiangiogenesis therapy.
31 patients with recurrent progressive stage III and IV
ovarian cancer with available tumor lysate from secondary
debulking surgery enrolled in two different studies. First 6
underwent priming with intravenous bevacizumab and
oral metronomic cyclophosphamide followed by vaccina-
tion with an autologous DC preparation pulsed with
freeze-thaw autologous tumor lysate while the other 25
underwent vaccination with an enhanced vaccine where
autologous DCs were loaded with HOCl-oxidized autolo-
gous tumor lysate administered intranodally every 2 weeks
in combination with intravenous bevacizumab. Both
studies were followed by lymphodepletion and transfer
of autologous vaccine-primed, ex vivo CD3/CD28-
costimulated peripheral blood T-cells, in combination
with antiangiogenesis therapy and vaccination. Feasibility,
safety, and biological and clinical efficacy were evaluated.
Eleven subjects have completed vaccination and T cell
transfer to date, while twenty-three additional subjects
completed vaccination only. Vaccination was well toler-
ated and elicited tumor-specific T cell responses against
various ovarian tumor antigen in both studies and a clini-
cal benefit of 65% correlated with the immune response
with some experiencing prolonged progression free survi-
val. Preliminary results demonstrate that patients’ DCs
loaded with HOCl-oxidized lysate elicited strong tumor-
specific IFN-g secretions when incubated with autologous
T cells post vaccination. These DC’s also produced high
levels of Th1-priming cytokines and chemokines, includ-
ing IL-12. Following lymphodepletion, adoptive transfer of
vaccine-primed T-cells was well tolerated and resulted in
durable reduction of T-regulatory cells and restoration of
vaccine-induced antitumor immunity in patients who
experienced clinical benefit. eight out of 11 patients
exhibited clinical benefit with one patient achieving a
complete response at end of study. Stable disease was
observed in 7 subjects to date. Data on additional patients
will be presented at the meeting. Our results suggest the
use of combinatorial cellular immunotherapy comprising
DC vaccination with whole tumor antigen and adoptive
lymphocyte transfer using tumor antigen-specific T cells
for the treatment of patients with recurrent ovarian cancer
is promising yet warrants further investigation.
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